Analytical Method Development

Requirement ICH Q3D(R2), “Guideline for Elemental Impurities,” reached Step 4 on 26 April 2022, correcting the permitted daily exposure (PDE) values for gold, silver, and nickel from the prior Q3D(R1) and adding a new appendix. FDA adopted it via Federal Register notice on September 15, 2022.

Figure F1.1

F1.1  PDEs, element classes, and the control threshold

Requirement Q3D(R2) sets a Permitted Daily Exposure (PDE), in micrograms per day, for each element of concern, varying by route of administration — parenteral and inhalation routes generally get tighter PDEs than oral. Elements are sorted into four classes: Class 1 (arsenic, cadmium, lead, mercury — significant toxicants, always considered regardless of likelihood of presence), Class 2A (cobalt, nickel, vanadium — high probability of occurrence, requiring a full risk assessment across all routes), Class 2B (lower probability unless intentionally added), and Class 3 (lower oral toxicity, but still evaluated for parenteral and inhalation routes).

Requirement The manufacturer must document a risk assessment spanning four potential sources: the drug substance, excipients, manufacturing equipment, and the container closure system. A realistic contribution above 30% of an element's PDE — the control threshold — triggers additional controls. That 30% figure is not incidental; it becomes the practical target Module F2's worked example is built around.

F1.2  USP ⟨232⟩ and ⟨233⟩

Requirement USP General Chapter ⟨232⟩, “Elemental Impurities—Limits,” was developed in parallel with, and harmonized to, ICH Q3D — it translates the same PDE-derived limits and element classes into enforceable compendial concentration limits. USP ⟨233⟩, “Elemental Impurities—Procedures,” is the companion chapter describing ICP-MS and ICP-OES as the default validated techniques (not the only permitted ones), and specifying the validation elements — accuracy and recovery, precision, specificity, LOQ, linearity, range — mirroring ICH Q2 expectations directly.

---

F2.1  When each technique is preferred

Practice ICP-MS ionizes the sample and separates ions by mass-to-charge ratio, reaching detection limits in the low parts-per-trillion to parts-per-billion range — the default choice for Class 1 elements and for parenteral/inhalation products with tight PDEs, though it is susceptible to polyatomic and isobaric mass interferences, generally addressed with collision or reaction cells. ICP-OES measures characteristic emitted light instead, generally less sensitive (parts-per-billion to low parts-per-million) but more robust to some matrix effects, and typically cheaper and faster — often entirely adequate for higher-concentration or more permissive Class 2A/3 work.

Practice Both techniques share the same practical validation concerns: complete sample digestion (incomplete digestion is a common root cause of recovery failures — the element was in the sample, but never got into solution where the instrument could see it), and NIST-traceable calibration standards, validated for recovery, precision, specificity, linearity, and an LOQ below the threshold that actually matters.

F2.2  “Below the threshold that matters,” worked as a real number

Take a Class 1 element — lead, PDE = 5 µg/day by the oral route — in a drug product with an assumed maximum daily dose of 2 g/day. USP ⟨232⟩'s concentration limit is the PDE divided by the maximum daily dose: 5 µg/day ÷ 2 g/day =  2.50 ppm. Module F1's 30% control threshold is 0.750 ppm. An ICP-MS method intended to support this product needs an LOQ comfortably below that number, not just below the full specification limit.

Figure F2.1

A six-point calibration series, computed the same way Arc A3 first introduced — ordinary least-squares regression across concentration and instrument response — gives a slope of 48220 counts per second per ppm, R² = 1.0000, and a regression-based LOQ (10×residual SD÷ slope, the same formula used for the calibration worked example in Arc A) of 0.018 ppm.

Practice 0.018 ppm sits well below both the 0.750 ppm control threshold and the 2.50 ppm specification limit — the quantitative demonstration that this method can actually see the level that matters, not merely a plausible claim that ICP-MS is “sensitive enough” in the abstract. This is exactly the kind of number a validation report has to produce before an elemental-impurities method is trusted for release testing, and exactly the kind of gap — asserting sensitivity instead of demonstrating it against a specific limit — that shows up in Module F3's case study.

---

F3.1  Glenmark Pharmaceuticals Limited — a gap assessment with a gap in it

“Your gap assessment does not adequately address the lack of reference to method validation or verification studies for all appropriate methods, such as your in-house (b)(4) testing and in-house elemental impurities testing.”Glenmark Pharmaceuticals Limited — Warning Letter, July 11, 2025. fda.gov (21 CFR 211.160(b))

Practice Read against Arc A2: this firm's own gap assessment — the exercise meant to find exactly this kind of hole — did not catch that its in-house elemental impurities testing had no documented validation or verification behind it. A control meant to catch missing validation is not self-verifying; someone still has to confirm the gap assessment itself actually covered every method it claimed to.

F3.2  MiMedx Group, Inc. — flagged honestly as a different kind of case

“…your firm has failed to include specifications for elemental impurities and endotoxin”MiMedx Group, Inc. — Warning Letter, December 20, 2023. fda.gov